Asia-Pacific Human Insulin Market Overview: 2024-2030
Base Year: 2023
Historical Years: 2019-22
Forecast Years: 2024-2030
The Asia-Pacific Human Insulin Market is estimated to grow at a CAGR of around 8.12% during the forecast period, i.e., 2024-30.
Our Latest Reports Now Include In-Depth Supply Chain Ecosystem Analysis, Enabling Businesses to Navigate Tariff Challenges with Greater Agility Get Sample Report – https://www.marknteladvisors.com/query/request-sample/apac-human-insulin-market.html
Asia-Pacific Human Insulin Market Dynamics: 2024-2030
Asia-Pacific Human Insulin Market Driver:
Surging Prevalence of Diabetes Boosting the Human Insulin Market – The Asia-Pacific Human Insulin Market has witnessed robust growth driven by a surge in diabetes prevalence over the historical years. This has been primarily attributed to factors such as changing lifestyles, increased obesity rates, and an aging population. Asia-Pacific aging demographics have also played a pivotal role as older individuals are more prone to diabetes. According to the Economic and Social Commission for Asia and the Pacific, the number of older persons is projected to more than double, from around 630 million in 2020 to about 1.3 billion by 2050. Hence, as the world experiences a demographic shift towards an older age structure, the prevalence of diabetes is on the rise. This demographic trend amplifies the demand for human insulin, which has aided in driving the Asia-Pacific Human Insulin Market.
Browse Full Report with Detail Analysis – https://www.marknteladvisors.com/research-library/apac-human-insulin-market.html
Asia-Pacific Human Insulin Market (2024-30): Segmentation Outlook
The market report has segmented the market into the following categories:
By Type
-Human Insulin Biologics – Market Size & Forecast 2019-2030, USD Million
-Intermediate Acting- Market Size & Forecast 2019-2030, USD Million
-Short Acting- Market Size & Forecast 2019-2030, USD Million
-Premixed- Market Size & Forecast 2019-2030, USD Million
-Insulin Analogue & Biosimilar – Market Size & Forecast 2019-2030, USD Million
-Long Acting- Market Size & Forecast 2019-2030, USD Million
-Rapid Acting- Market Size & Forecast 2019-2030, USD Million
-Premixed- Market Size & Forecast 2019-2030, USD Million
By Application
-Diabetes Type 1- Market Size & Forecast 2019-2030, USD Million
-Diabetes Type 2- Market Size & Forecast 2019-2030, USD Million
By End Users
-Hospital/Clinics- Market Size & Forecast 2019-2030, USD Million
-Home/Personal- Market Size & Forecast 2019-2030, USD Million
By Distribution Channel
-Hospital Pharmacies- Market Size & Forecast 2019-2030, USD Million
-Retail Pharmacies- Market Size & Forecast 2019-2030, USD Million
-Online Pharmacies- Market Size & Forecast 2019-2030, USD Million
By Country
-China
-Japan
-India
-Australia
-South Korea
-Thailand
-Rest of Asia-Pacific.
Note – If there are any particular details you need that are not currently included in the report, we will be happy to provide them as part of our customization services.
Top Companies Operating in the Asia-Pacific Human Insulin Market:
Becton, Dickinson and Company (BD), Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals, Wockhardt Limited, Lupin Limited, Novo Nordisk A/S, Eris Lifesciences, Sanofi, Tonghua Dongbao Pharmaceutical Co., Ltd, and others.
Market Recent Development:
- 2023: Novo Nordisk, launched once-a-week insulin regime for Indian patients. The company is conducting trials in around 27 sites involving 217 patients in India.
- 2023: Lilly Eli Lilly and Company, supplied its active pharmaceutical ingredient (API) for human insulin at a reduced price to International Agencies (Bangladesh) Ltd. (IABL) in an effort to increase patient access & improve affordability for high-quality insulin for nearly one million customers living with diabetes in Bangladesh by 2030.
Reports Delivery Format – Market research studies from MarkNtel Advisors are offered in PDF, Excel, and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address
About Us –
We are a leading market research company, consulting, & data analytics firm that provides an extensive range of strategic reports on diverse industry verticals. We deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, & individuals, among others.
Our specialization in niche industries & emerging geographies allows our clients to formulate their strategies in a much more informed way and entail parameters like Go-to-Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, & trend analysis, among others, for 15 diverse industrial verticals.
Contact Us –
Email: sales@marknteladvisors.com
Sales Office: 564 Prospect St, B9, New Haven, Connecticut, USA-06511
Address Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India
